Capital Asset Advisory Services LLC Sells 5,853 Shares of Abbott Laboratories $ABT

Capital Asset Advisory Services LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 13.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,485 shares of the healthcare product maker’s stock after selling 5,853 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Abbott Laboratories were worth $3,695,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ABT. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 1.6%

Shares of ABT opened at $92.15 on Thursday. The stock’s 50-day moving average price is $88.83 and its 200 day moving average price is $104.62. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $160.51 billion, a price-to-earnings ratio of 25.81, a P/E/G ratio of 1.56 and a beta of 0.61. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company earned $1.09 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott Laboratories with an Outperform rating and a $121 price target, signaling strong upside potential and renewed Wall Street confidence. Article Title
• Positive Sentiment: Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which could expand Abbott’s CGM ecosystem and support diabetes-care sales. Article Title
• Positive Sentiment: Wells Fargo reiterated a Buy rating on Abbott Laboratories, adding to the positive analyst sentiment around the stock. Article Title
• Positive Sentiment: TipRanks highlighted Abbott as one of the dividend aristocrats that Wall Street currently likes, reinforcing the view that it remains a favored defensive healthcare name. Article Title
• Neutral Sentiment: Recent coverage compared Abbott with Intuitive Surgical, but the article was more of a broader healthcare-stock debate than a direct catalyst for Abbott’s shares. Article Title
• Neutral Sentiment: Abbott-related commentary on multi-cancer blood screening and broader healthcare trends is informative for the sector, but it does not appear to be a direct company-specific catalyst. Article Title
• Negative Sentiment: Abbott also faced headlines about a closed U.S. criminal probe into its infant-formula plant and a proposed civil settlement, which could remain a legal overhang even if the worst-case risk has eased. Article Title

Analyst Ratings Changes

ABT has been the subject of several recent analyst reports. Wells Fargo & Company decreased their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Benchmark cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Leerink Partners lowered their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday. They set an “outperform” rating and a $121.00 target price on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a research note on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $118.42.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.